MX2024010392A - Remibrutinib para el uso en el tratamiento de hidradenitis supurativa. - Google Patents

Remibrutinib para el uso en el tratamiento de hidradenitis supurativa.

Info

Publication number
MX2024010392A
MX2024010392A MX2024010392A MX2024010392A MX2024010392A MX 2024010392 A MX2024010392 A MX 2024010392A MX 2024010392 A MX2024010392 A MX 2024010392A MX 2024010392 A MX2024010392 A MX 2024010392A MX 2024010392 A MX2024010392 A MX 2024010392A
Authority
MX
Mexico
Prior art keywords
hidradenitis suppurativa
remibrutinib
treatment
methods
disclosed
Prior art date
Application number
MX2024010392A
Other languages
English (en)
Spanish (es)
Inventor
Christian Loesche
Bruno Bieth
Michael Juhnke
Souvik Bhattacharya
Bruno Cenni
Karin Rapp
Kim - Hien Sin
Gordon Graham
Jonas Benjamin Zierer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2024010392A publication Critical patent/MX2024010392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024010392A 2022-02-28 2023-02-27 Remibrutinib para el uso en el tratamiento de hidradenitis supurativa. MX2024010392A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US202263369016P 2022-07-21 2022-07-21
PCT/IB2023/051787 WO2023161887A1 (en) 2022-02-28 2023-02-27 Remibrutinib for use in the treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
MX2024010392A true MX2024010392A (es) 2024-09-06

Family

ID=85570288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010392A MX2024010392A (es) 2022-02-28 2023-02-27 Remibrutinib para el uso en el tratamiento de hidradenitis supurativa.

Country Status (11)

Country Link
US (1) US20250099465A1 (https=)
EP (1) EP4486346A1 (https=)
JP (2) JP7696006B2 (https=)
KR (1) KR20240155278A (https=)
CN (1) CN120617264A (https=)
AU (1) AU2023225222A1 (https=)
CA (1) CA3251002A1 (https=)
IL (1) IL314205A (https=)
MX (1) MX2024010392A (https=)
TW (1) TW202342048A (https=)
WO (1) WO2023161887A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CR20180285A (es) 2015-11-26 2018-07-16 Novartis Ag Derivados novedosos de diamino piridina
RU2749547C2 (ru) 2016-09-23 2021-06-15 Новартис Аг Индазольные соединения для применения при повреждениях сухожилий и/или связок
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP3849559A4 (en) * 2018-09-12 2022-06-01 Denovo Biopharma LLC COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
CN113840821A (zh) 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
AU2021205248A1 (en) * 2020-01-08 2022-09-01 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
MX2023008671A (es) 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.

Also Published As

Publication number Publication date
WO2023161887A1 (en) 2023-08-31
TW202342048A (zh) 2023-11-01
EP4486346A1 (en) 2025-01-08
KR20240155278A (ko) 2024-10-28
CA3251002A1 (en) 2023-08-31
AU2023225222A1 (en) 2024-07-25
CN120617264A (zh) 2025-09-12
JP2024511938A (ja) 2024-03-18
JP2025134747A (ja) 2025-09-17
JP7696006B2 (ja) 2025-06-19
US20250099465A1 (en) 2025-03-27
IL314205A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CO2026004076A2 (es) Compuestos macrocíclicos, método de preparación de estos y uso de estos
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
AR045710A1 (es) Uso de inhibidores de tnf alfa y composiciones farmaceuticas que los comprenden para el tratamiento a dosis bajas
SV2006002256A (es) Uso de un anticuerpo para tratar la vasculitis
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR050418A1 (es) Dosificacion fija de anticuerpos her
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
AR071728A1 (es) Terapia con intervalos para el tratamiento del tinnitus
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
UY38948A (es) Régimen de dosificación para agentes anti-dll3
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
JOP20230278A1 (ar) تركيبة صيدلانية للوقاية من التليف أو علاجه
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
MX2025010161A (es) Conjugados de anticuerpo-farmaco que comprenden derivados de trabectedina y lurbinectedina
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
MX2024010392A (es) Remibrutinib para el uso en el tratamiento de hidradenitis supurativa.
MX2023005219A (es) Formulacion solida.
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
Dalkiran et al. Phantom limb pain treated with duloxetine: a case series
ZA202305383B (en) Topical administration of 2- (diethylamino) ethyl 2- (4-isobutylphenyl) propionate for treatment of diseases
AR105087A1 (es) Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona